98 related articles for article (PubMed ID: 16144664)
1. Inflammatory prostate cancer: an underestimated paraneoplastic clinical manifestation.
Mauri D; Pentheroudakis G; Tolis C; Chojnacka M; Pavlidis N
Urol Oncol; 2005; 23(5):318-22. PubMed ID: 16144664
[TBL] [Abstract][Full Text] [Related]
2. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy.
Moreau JP; Delavault P; Blumberg J
Clin Ther; 2006 Oct; 28(10):1485-508. PubMed ID: 17157109
[TBL] [Abstract][Full Text] [Related]
3. Disseminated, lethal prostate cancer during human immunodeficiency virus infection presenting with non-specific features. Open questions for urologists, oncologists, and infectious disease specialists.
Manfredi R; Fulgaro C; Sabbatani S; Dentale N; Legnani G
Cancer Detect Prev; 2006; 30(1):20-3. PubMed ID: 16455210
[TBL] [Abstract][Full Text] [Related]
4. Stauffer's syndrome with jaundice, a paraneoplastic manifestation of renal cell carcinoma: a case report.
Tomadoni A; García C; Márquez M; Ayala JC; Prado F
Arch Esp Urol; 2010 Mar; 63(2):154-6. PubMed ID: 20378939
[TBL] [Abstract][Full Text] [Related]
5. [Clinical features of urological malignancies with paraneoplastic syndromes].
Yang Y; Mao QZ; Li HZ; Rong S; Yan WG; Ji ZG; Liu GH; Xu WF; Xiao H; Wang HJ
Zhonghua Yi Xue Za Zhi; 2010 Dec; 90(48):3411-4. PubMed ID: 21223815
[TBL] [Abstract][Full Text] [Related]
6. Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE.
Abouassaly R; Paciorek A; Ryan CJ; Carroll PR; Klein EA
Cancer; 2009 Oct; 115(19):4470-6. PubMed ID: 19637339
[TBL] [Abstract][Full Text] [Related]
7. Human immunodeficiency virus-associated prostate cancer: clinicopathological findings and outcome in a multi-institutional study.
Pantanowitz L; Bohac G; Cooley TP; Aboulafia D; Dezube BJ
BJU Int; 2008 Jun; 101(12):1519-23. PubMed ID: 18384640
[TBL] [Abstract][Full Text] [Related]
8. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.
Small EJ; Carducci MA; Burke JM; Rodriguez R; Fong L; van Ummersen L; Yu DC; Aimi J; Ando D; Working P; Kirn D; Wilding G
Mol Ther; 2006 Jul; 14(1):107-17. PubMed ID: 16690359
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer.
Carver BS; Bianco FJ; Scardino PT; Eastham JA
J Urol; 2006 Aug; 176(2):564-8. PubMed ID: 16813890
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level.
Leibovici D; Spiess PE; Agarwal PK; Tu SM; Pettaway CA; Hitzhusen K; Millikan RE; Pisters LL
Cancer; 2007 Jan; 109(2):198-204. PubMed ID: 17171704
[TBL] [Abstract][Full Text] [Related]
11. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10.
Bastian PJ; Gonzalgo ML; Aronson WJ; Terris MK; Kane CJ; Amling CL; Presti JC; Mangold LA; Humphreys E; Epstein JI; Partin AW; Freedland SJ
Cancer; 2006 Sep; 107(6):1265-72. PubMed ID: 16900523
[TBL] [Abstract][Full Text] [Related]
12. Salvage hypofractionated radiotherapy for biochemically recurrent prostate cancer after radical prostatectomy.
Wong GW; Palazzi-Churas KL; Jarrard DF; Paolone DR; Graf AK; Hedican SP; Wegenke JD; Ritter MA
Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):449-55. PubMed ID: 17869014
[TBL] [Abstract][Full Text] [Related]
13. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes.
Cookson MS; Aus G; Burnett AL; Canby-Hagino ED; D'Amico AV; Dmochowski RR; Eton DT; Forman JD; Goldenberg SL; Hernandez J; Higano CS; Kraus SR; Moul JW; Tangen C; Thrasher JB; Thompson I
J Urol; 2007 Feb; 177(2):540-5. PubMed ID: 17222629
[TBL] [Abstract][Full Text] [Related]
14. External beam radiotherapy for clinically localized hormone-refractory prostate cancer: clinical significance of Nadir prostate-specific antigen value within 12 months.
Ogawa K; Nakamura K; Sasaki T; Onishi H; Koizumi M; Shioyama Y; Araya M; Mukumoto N; Mitsumori M; Teshima T;
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):759-65. PubMed ID: 19327908
[TBL] [Abstract][Full Text] [Related]
15. Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases.
Selander KS; Brown DA; Sequeiros GB; Hunter M; Desmond R; Parpala T; Risteli J; Breit SN; Jukkola-Vuorinen A
Cancer Epidemiol Biomarkers Prev; 2007 Mar; 16(3):532-7. PubMed ID: 17372249
[TBL] [Abstract][Full Text] [Related]
16. Prostate brachytherapy in men > or =75 years of age.
Merrick GS; Wallner KE; Galbreath RW; Butler WM; Brammer SG; Allen ZA; Adamovich E
Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):415-20. PubMed ID: 18374514
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer.
Semeniuk RC; Venner PM; North S
Urology; 2006 Sep; 68(3):565-9. PubMed ID: 17010728
[TBL] [Abstract][Full Text] [Related]
18. [Clinical features of pathologically confirmed metastatic bone tumors--a report of 390 cases].
Xu DL; Zhang XT; Wang GH; Li FB; Hu JY
Ai Zheng; 2005 Nov; 24(11):1404-7. PubMed ID: 16552972
[TBL] [Abstract][Full Text] [Related]
19. Early postoperative plasma transforming growth factor-beta1 is a strong predictor of biochemical progression after radical prostatectomy.
Shariat SF; Walz J; Roehrborn CG; Montorsi F; Jeldres C; Saad F; Karakiewicz PI
J Urol; 2008 Apr; 179(4):1593-7. PubMed ID: 18295256
[TBL] [Abstract][Full Text] [Related]
20. Outcome analysis of prostate cancer patients with pre-treatment PSA greater than 50 ng/ml.
Wiebe E; Rodrigues G; Lock M; D'Souza D; Stitt L
Can J Urol; 2008 Jun; 15(3):4078-83. PubMed ID: 18570713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
